VTGN Stock Summary and Trading Ideas (Vistagen Therapeutics | NASDAQ:VTGN)

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.

As of May 22, 2026, VTGN stock price climbed to $0.65 with 534,061 million shares trading.

VTGN has a beta of 0.83, meaning it tends to be less sensitive to market movements. VTGN has a correlation of 0.00 to the broad based SPY ETF.

VTGN has a market cap of $25.63 million. This is considered a Sub-Micro Cap stock.

Last quarter Vistagen Therapeutics reported $303,000 in Revenue and -$.45 earnings per share. This beat revenue expectation by $46,480 and missed earnings estimates by -$.06.

In the last 3 years, VTGN traded as high as $24.71 and as low as $.43.

The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL, IWC.

VTGN has underperformed the market in the last year with a return of -73.4%, while SPY returned +29.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VTGN shares. However, VTGN has outperformed the market in the last 3 month and 2 week periods, returning +15.7% and +6.0%, while SPY returned +8.4% and +1.1%, respectively. This indicates VTGN has been having a stronger performance recently.

VTGN support price is $.61 and resistance is $.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.